Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 17.74.
Forward PE Ratio (17.74) = Close Price ($250.27) / Consensus Forward EPS ($14.03)
FORWARD PE RATIO
17.74
SECTOR MEDIAN · HEALTHCARE
19.84
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
-10.56%
vs the sector median at left
AbbVie Inc.
Market Cap
$442.18B
Forward PE Ratio
17.74
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| AbbVie Inc. (ABBV) | $442.18B | 17.74 |
| Merck & Co., Inc. (MRK)vs › | $367.24B | 54.00 |
| Roche Holding AG (RHHBY)vs › | $345.60B | 22.08 |
| UnitedHealth Group Incorporated (UNH)vs › | $345.58B | 20.29 |
| AstraZeneca PLC (AZN)vs › | $246.27B | 15.63 |
| Johnson & Johnson (JNJ)vs › | $649.81B | 23.23 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $223.06B | 24.01 |
| Amgen Inc. (AMGN)vs › | $213.06B | 17.04 |
| Novo Nordisk A/S (NVO)vs › | $200.85B | N/A |
| Abbott Laboratories (ABT)vs › | $183.96B | 19.13 |
Trailing P/E
70.1
reported TTM EPS
Forward P/E
17.7
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $14.03 implies +295.2% EPS growth vs the reported trailing $3.55.
At today's $250.27 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $14.03 | $13.88 – $14.52 | 15 | 17.8x |
| 2027-12-31 | $16.32 | $15.36 – $17.56 | 14 | 15.3x |
| 2028-12-31 | $17.92 | $15.49 – $21.55 | 8 | 14.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute